Proxima Capital Management LLC maintained its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Alexion Pharmaceuticals accounts for approximately 1.0% of Proxima Capital Management LLC’s investment portfolio, making the stock its 27th largest position. Proxima Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,825,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of ALXN. Neuberger Berman Group LLC increased its holdings in Alexion Pharmaceuticals by 29.9% during the 1st quarter. Neuberger Berman Group LLC now owns 6,189 shares of the biopharmaceutical company’s stock worth $750,000 after purchasing an additional 1,423 shares in the last quarter. Teachers Advisors LLC increased its holdings in Alexion Pharmaceuticals by 3.0% during the 1st quarter. Teachers Advisors LLC now owns 422,267 shares of the biopharmaceutical company’s stock worth $51,196,000 after purchasing an additional 12,179 shares in the last quarter. Laurion Capital Management LP bought a new stake in Alexion Pharmaceuticals during the 1st quarter worth approximately $10,790,000. PNC Financial Services Group Inc. increased its holdings in Alexion Pharmaceuticals by 2.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 50,643 shares of the biopharmaceutical company’s stock worth $6,141,000 after purchasing an additional 1,285 shares in the last quarter. Finally, Verity Asset Management Inc. bought a new stake in Alexion Pharmaceuticals during the 1st quarter worth approximately $294,000. 94.25% of the stock is owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down 0.49% during trading on Friday, reaching $140.77. The company had a trading volume of 291,361 shares. The firm has a market capitalization of $31.42 billion, a PE ratio of 61.05 and a beta of 1.39. The firm’s 50 day moving average price is $142.03 and its 200 day moving average price is $126.93. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the previous year, the firm posted $1.13 EPS. The firm’s revenue was up 21.1% on a year-over-year basis. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.
WARNING: This story was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thestockobserver.com/2017/10/13/proxima-capital-management-llc-holds-holdings-in-alexion-pharmaceuticals-inc-alxn.html.
A number of analysts have commented on the company. SunTrust Banks, Inc. reissued a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann reissued a “buy” rating and set a $182.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective for the company. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $154.56.
In other news, EVP Julie O’neill sold 4,375 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the transaction, the executive vice president now owns 26,092 shares in the company, valued at approximately $3,794,820.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is currently owned by insiders.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.